Cancer Immunology and Immunotherapy
Cancer Immunology and Immunotherapy

Author: Mansoor M. Amiji

Publisher: Academic Press

Published: 2021-08-18

Total Pages: 550

ISBN-13: 012823637X

DOWNLOAD EBOOK

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO

Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor, volume II
Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor, volume II

Author: Xi Cheng

Publisher: Frontiers Media SA

Published: 2023-12-13

Total Pages: 213

ISBN-13: 2832540821

DOWNLOAD EBOOK

This Research Topic is the second volume of the “Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor". Please Volume I here. The microenvironment of tumors is consisted of the tumor stroma, proliferating tumor cells, infiltrating inflammatory cells, blood vessels, and various associated tissue cells. The pre-metastatic niche (PRN) is described as supportive and receptive, which undergoes cellular and molecular changes to form the fertile “soil” or metastatic-designated sites for metastatic tumor cell “seed” colonization. Thus, the PRN supports promoting tumor metastasis and tumor settlement in distant organs. The infiltration of the immune cells and the formation of blood vessels from the pre-metastatic sites are critical for the tumor microenvironment. Typically, the angiogenic factor is strongly associated with the inflammatory response during the development of tumors. Additionally, the immunoediting processes are essentially devoted to promoting angiogenesis and modulating the innate and specific immune responses.

Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II
Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II

Author:

Publisher: Frontiers Media SA

Published: 2024-01-10

Total Pages: 261

ISBN-13: 2832541933

DOWNLOAD EBOOK

This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.

Community Series in Resident Memory T Cells: Guardians of the Balance of Local Immunity and Pathology, Volume II
Community Series in Resident Memory T Cells: Guardians of the Balance of Local Immunity and Pathology, Volume II

Author: Nick P. Goplen

Publisher: Frontiers Media SA

Published: 2024-06-20

Total Pages: 136

ISBN-13: 2832550525

DOWNLOAD EBOOK

As we learn more about the intricacies of immune interactions, the goalposts of ideal vaccination strategies change. It has become apparent that for many pathogens, immunizations should seek to optimize lymphocyte-mediated protection at their portals of entry, which is not likely to be accomplished with current intramuscular jabs. However, there are increased reports suggesting resident memory CD4 and CD8 T cells may, or indeed do, cause pathologies in the lung, gut, skin, pancreas, CNS, and adipose tissue. This is following chronic infection, immunization, or sensitization and it is becoming clearer that protective immunity ought to be finely balanced with the pathogenic capacity of the resident cells providing the immunity. Alternatively, in instances like asthma or inflammatory bowel disease (IBD) where the bulk of resident CD4 or CD8T cells’ pathogenic capacity is not restrained, understanding the mechanisms of escape from immune regulation may be key. Thus we are interested in soliciting works that seek to provide a deeper mechanistic understanding of the balance of immunity and pathology that local resident memory T cells must successfully display in order to build upon the existing dogma regarding ideal vaccination strategies.